Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emodepside multiple-dose safety and PK in healthy males
NCT03383614Phase 1Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Nov 2017
- Primary completion
- Oct 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of emodepside in onchocerciasis (3 cohorts), sponsored by Drugs for Neglected Diseases initiative. Primary endpoints: Number of Participants With Adverse Events up to 120 days, Number of Participants With Vital Signs Findings up to 120 days and 4 more. Started Nov 2017; status: completed.
02
Drugs
emodepside
03
Conditions
onchocerciasis
Beyond the preview
Go deeper on NCT03383614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03383614.